1. Show article details.

    Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS

    PR Newswire – 12:28 PM ET 04/10/2014

    NEW YORK, April 10, 2014 Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (PBYI), Alnylam Pharmaceuticals, Inc. (ALNY), INSYS Therapeutics, Inc. (INSY), Peregrine Pharmaceuticals Inc. (PPHM), and VIVUS Inc. Private wealth members receive these notes ahead of publication.

  2. Show article details.

    Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer

    Market Wire – 11:00 AM ET 04/09/2014

    04/09/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced data from studies validating the immune-stimulatory mechanism of action of bavituximab and demonstrating that the combination of a preclinical phosphatidylserine-targeting antibody with the immune checkpoint inhibitors anti-CTLA-4 or anti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma and col...

  3. Show article details.

    Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma

    PR Newswire – 1:15 PM ET 04/08/2014

    LONDON, April 8, 2014 The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative.

  4. Show article details.

    Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer

    Market Wire – 8:00 AM ET 04/07/2014

    04/07/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy showed a 100% improvement i...

  5. Show article details.

    Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting

    Market Wire – 4:00 PM ET 04/01/2014

    04/01/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 105th Annual Meeting of the American Association for Cancer Research, to be held April 5-9, 2014 in San Diego, California.

  6. Show article details.

    Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer

    Market Wire – 8:00 AM ET 03/14/2014

    03/14/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the presentation of an update to the ongoing Investigator-Sponsored Trial of its immunotherapy bavituximab in combination with the chemotherapy sorafenib in patients with advanced hepatocellular carcinoma or liver cancer.

  7. Show article details.

    Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies

    Market Wire – 8:00 AM ET 03/13/2014

    03/13/14 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine-targeting antibodies in both oncology and antiviral therapeutic areas.

  8. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    Market Wire – 4:10 PM ET 03/11/2014

    03/11/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2014 to holders of record at the close of business on March 21, 2014.

  9. Show article details.

    Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies

    Market Wire – 8:00 AM ET 03/11/2014

    03/11/14 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models.

  10. Show article details.

    Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments

    Market Wire – 8:00 AM ET 03/07/2014

    03/07/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.

  11. Show article details.

    Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide

    PR Newswire – 10:40 AM ET 03/05/2014

    LONDON, March 5, 2014 Editor Note: For more information about this release, please scroll to bottom.

  12. Show article details.

    Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences

    Market Wire – 4:00 PM ET 03/04/2014

    03/04/14 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014.

  13. Show article details.

    Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014

    Market Wire – 4:00 PM ET 02/27/2014

    02/27/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the third quarter of fiscal year 2014 on March 7, 2014 before market opens and will host a conference call and webcast at 8:00 a.m. Pacific Time.

  14. Show article details.

    Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering

    Market Wire – 12:18 PM ET 02/27/2014

    02/27/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), announced today that the underwriters of its underwritten public offering of its 10.50% Series E Convertible Preferred Stock have partially exercised their option to cover overallotments and have purchased an additional 75,000 shares of Series E Preferred Stock from Peregrine Pharmaceuticals (PPHM) at the public offering price of $25.00 per share.

  15. Show article details.

    Peregrine Pharmaceuticals Announces Upcoming Events

    Market Wire – 4:00 PM ET 02/19/2014

    02/19/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that the company will participate in the following investor conferences: 2014 RBC Capital Markets' Global Healthcare Conference Date: Tuesday, February 25, 2014 Time: 2:05 PM Eastern Time Location: The New Yo...

  16. Show article details.

    Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering

    Market Wire – 10:15 AM ET 02/19/2014

    02/19/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), announced today that it has closed its previously announced underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public offering price of $25.00 per share. MLV & Co. LLC acted as sole book-runner for the offering.

  17. Show article details.

    Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock

    Market Wire – 8:00 AM ET 02/11/2014

    02/11/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), announced today that it has priced an underwritten public offering of 700,000 shares of its 10.50% Series E Convertible Preferred Stock at a public offering price of $25.00 per share. The offering is being made pursuant to the Company's existing effective shelf registration statement, previously filed with the Securities and Exchange Commission.

  18. Show article details.

    Peregrine Pharmaceuticals Announces Public Offering of Series E Preferred Stock

    Market Wire – 4:01 PM ET 02/05/2014

    02/05/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), announced today that it intends to offer and sell shares of its newly-designated 10.50% Series E Convertible Preferred Stock, in an underwritten public offering. MLV & Co. LLC is acting as sole book-running manager; Maxim Group LLC and National Securities Corporation are acting as co-managers for the proposed offering.

  19. Show article details.

    Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer

    Market Wire – 7:30 AM ET 01/06/2014

    01/06/14 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced that the company has received Fast Track designation by the U.S. Food and Drug Administration for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer.

  20. Show article details.

    Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

    Market Wire – 7:30 AM ET 12/30/2013

    12/30/13 -- Peregrine Pharmaceuticals, Inc. (PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. "The design of the SUNRISE trial was based on the compelling Phase II data demonstrating encouraging improvement in overall survival in patients with second-line NSCLC.

Page:

Today's and Upcoming Events

  • Jul
    10

    PPHM to announce Q4 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    7

    PPHM Earnings Conference Call at 11:00 AM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.